CNBC contributor Barbara Ryan of Clermont Partners, discusses whether biotech is a good place to be right now, and how investors
Eric Schmidt, Cowen & Co. biotech analyst, thinks biotech will continue to be a great business and will move higher. Insight, with Geoff Porges, Sanford Bernstein.
A new antibiotic-resistant "superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. What companies may be on track to combat the deadly virus, with CNBC's Meg Tirrell.
New DNA evidence says significant chunks of humanity may carry genes from a few powerful men, including Genghis Khan.
Caterpillar and 3Ms' poor earnings performance "spooked investors", however tech and healthcare are expected to save the earnings season, says Christine Short, senior vice president at Estimize.
Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discusses his role in the company.
CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.
CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.
The biotechs were one of the best performing sectors for 2014. Can it work wonders for 2015? Cramer gives his top players in the biotech space.
A total of 71 biotech companies went public in 2014. Cowen Group President and Cowen & Company CEO Jeffrey Solomon, discusses the market sentiment toward the sector.
Discussing the outlook on the pharmaceutical sector, including leaders like Gilead and Celgene, with Michael Yee, RBC Capital Markets biotech analyst.
Gilead Sciences is lifting the biotech sector higher in today's trade, reports CNBC's Meg Tirrell.
Biotech finished 2014 up 44 percent. David Seaburg, thinks biotech will outperform the S&P 500 this year, but there could be some suffering mid-year.